Skip to main content
Top
Published in: Angiogenesis 1/2014

01-01-2014 | Original Paper

Proangiogenic microtemplated fibrin scaffolds containing aprotinin promote improved wound healing responses

Authors: Kassandra S. Thomson, Sarah K. Dupras, Charles E. Murry, Marta Scatena, Michael Regnier

Published in: Angiogenesis | Issue 1/2014

Login to get access

Abstract

Survival of tissue engineered constructs after implantation depends heavily on induction of a vascular response in host tissue, promoting a quick anastomosis of the cellular graft. Additionally, implanted constructs typically induce fibrous capsule formation, effectively preventing graft integration with host tissue. Previously we described the development of a high density microtemplated fibrin scaffold for cardiac tissue engineering applications with tunable degradation and mechanical properties which promoted seeded cell survival and organization in vitro (Thomson et al., Tissue Eng Part A, 2013). Scaffold degradation in vitro was controllable by addition of the serine protease inhibitor aprotinin and/or the fibrin cross-linker Factor XIII (FXIII). The goal of this study was to assess host tissue responses to these fibrin scaffold formulations by determining effects on scaffold degradation, angiogenic responses, and fibrous capsule formation in a subcutaneous implant model. Aprotinin significantly decreased scaffold degradation over 2 weeks of implantation. A significant increase in capillary infiltration of aprotinin implants was found after 1 and 2 weeks, with a significantly greater amount of capillaries reaching the interior of aprotinin scaffolds. Interestingly, after 2 weeks the aprotinin scaffolds had a significantly thinner, yet apparently more cellular fibrous capsule than unmodified scaffolds. These results indicate aprotinin not only inhibits fibrin scaffold degradation, but also induces significant responses in the host tissue. These included an angiogenic response resulting in increased vascularization of the scaffold material over a relatively short period of time. In addition, aprotinin release from scaffolds may reduce fibrous capsule formation, which could help promote improved integration of cell-seeded scaffolds with host tissue.
Literature
1.
go back to reference Thomson KS, Korte FS, Giachelli CM, Ratner BD, Regnier M, Scatena M (2013) Prevascularized microtemplated fibrin scaffolds for cardiac tissue engineering applications. Tissue Eng Part A 19(7–8):967–977 Thomson KS, Korte FS, Giachelli CM, Ratner BD, Regnier M, Scatena M (2013) Prevascularized microtemplated fibrin scaffolds for cardiac tissue engineering applications. Tissue Eng Part A 19(7–8):967–977
3.
go back to reference Naderi H, Matin MM, Bahrami AR (2011) Review paper: critical issues in tissue engineering: biomaterials, cell sources, angiogenesis, and drug delivery systems. J Biomater Appl 26:383PubMedCrossRef Naderi H, Matin MM, Bahrami AR (2011) Review paper: critical issues in tissue engineering: biomaterials, cell sources, angiogenesis, and drug delivery systems. J Biomater Appl 26:383PubMedCrossRef
4.
go back to reference Anderson JM (2001) Biological responses to materials. Annu Rev Mater Res 31:81CrossRef Anderson JM (2001) Biological responses to materials. Annu Rev Mater Res 31:81CrossRef
5.
go back to reference Cosson M, Debodinance P, Boukerrou M, Chauvet MP, Lobry P, Crépin G, Ego A (2003) Mechanical properties of synthetic implants used in the repair of prolapse and urinary incontinence in women: which is the ideal material? Int Urogynecol J Pelvic Floor Dysfunct 14:169PubMedCrossRef Cosson M, Debodinance P, Boukerrou M, Chauvet MP, Lobry P, Crépin G, Ego A (2003) Mechanical properties of synthetic implants used in the repair of prolapse and urinary incontinence in women: which is the ideal material? Int Urogynecol J Pelvic Floor Dysfunct 14:169PubMedCrossRef
6.
go back to reference Kidd KR, Nagle RB, Williams SK (2002) Angiogenesis and neovascularization associated with extracellular matrix-modified porous implants. J Biomed Mater Res 59:366PubMedCrossRef Kidd KR, Nagle RB, Williams SK (2002) Angiogenesis and neovascularization associated with extracellular matrix-modified porous implants. J Biomed Mater Res 59:366PubMedCrossRef
7.
go back to reference Bootle-Wilbraham C, Tazzyman S, Thompson W, Stirk C, Lewis C (2001) Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. Angiogenesis 4:269PubMedCrossRef Bootle-Wilbraham C, Tazzyman S, Thompson W, Stirk C, Lewis C (2001) Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. Angiogenesis 4:269PubMedCrossRef
8.
go back to reference Ge M, Ryan TJ, Lum H, Malik AB (1991) Fibrinogen degradation product fragment D increases endothelial monolayer permeability. Am J Physiol 261:L283PubMed Ge M, Ryan TJ, Lum H, Malik AB (1991) Fibrinogen degradation product fragment D increases endothelial monolayer permeability. Am J Physiol 261:L283PubMed
9.
go back to reference Monroe DM, Hoffman M (2006) What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26:41PubMedCrossRef Monroe DM, Hoffman M (2006) What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26:41PubMedCrossRef
10.
go back to reference Ahmed TA, Dare EV, Hincke M (2008) Fibrin: a versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev 14:199PubMedCrossRef Ahmed TA, Dare EV, Hincke M (2008) Fibrin: a versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev 14:199PubMedCrossRef
11.
go back to reference Barsotti MC, Felice F, Balbarini A, Di Stefano R (2011) Fibrin as a scaffold for cardiac tissue engineering. Biotechnol Appl Biochem 58:301PubMedCrossRef Barsotti MC, Felice F, Balbarini A, Di Stefano R (2011) Fibrin as a scaffold for cardiac tissue engineering. Biotechnol Appl Biochem 58:301PubMedCrossRef
12.
go back to reference Chen X, Aledia AS, Ghajar CM, Griffith CK, Putnam AJ, Hughes CC, George SC (2009) Prevascularization of a fibrin-based tissue construct accelerates the formation of functional anastomosis with host vasculature. Tissue Eng Part A 15:1363PubMedCrossRef Chen X, Aledia AS, Ghajar CM, Griffith CK, Putnam AJ, Hughes CC, George SC (2009) Prevascularization of a fibrin-based tissue construct accelerates the formation of functional anastomosis with host vasculature. Tissue Eng Part A 15:1363PubMedCrossRef
13.
go back to reference Giraud MN, Ayuni E, Cook S, Siepe M, Carrel TP, Tevaearai HT (2008) Hydrogel-based engineered skeletal muscle grafts normalize heart function early after myocardial infarction. Artif Organs 32:692PubMedCrossRef Giraud MN, Ayuni E, Cook S, Siepe M, Carrel TP, Tevaearai HT (2008) Hydrogel-based engineered skeletal muscle grafts normalize heart function early after myocardial infarction. Artif Organs 32:692PubMedCrossRef
14.
go back to reference Ryu JH, Kim IK, Cho SW, Cho MC, Hwang KK, Piao H, Piao S, Lim SH, Hong YS, Choi CY, Yoo KJ, Kim BS (2005) Implantation of bone marrow mononuclear cells using injectable fibrin matrix enhances neovascularization in infarcted myocardium. Biomaterials 26:319PubMedCrossRef Ryu JH, Kim IK, Cho SW, Cho MC, Hwang KK, Piao H, Piao S, Lim SH, Hong YS, Choi CY, Yoo KJ, Kim BS (2005) Implantation of bone marrow mononuclear cells using injectable fibrin matrix enhances neovascularization in infarcted myocardium. Biomaterials 26:319PubMedCrossRef
15.
go back to reference Christman KL, Fok HH, Sievers RE, Fang Q, Lee RJ (2004) Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 10:403PubMedCrossRef Christman KL, Fok HH, Sievers RE, Fang Q, Lee RJ (2004) Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 10:403PubMedCrossRef
16.
go back to reference Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH, Lee RJ (2004) Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 44:654PubMedCrossRef Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH, Lee RJ (2004) Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 44:654PubMedCrossRef
17.
go back to reference Chekanov V, Akhtar M, Tchekanov G, Dangas G, Shehzad MZ, Tio F, Adamian M, Colombo A, Roubin G, Leon MB, Moses JW, Kipshidze NN (2003) Transplantation of autologous endothelial cells induces angiogenesis. Pacing Clin Electrophysiol 26:496PubMedCrossRef Chekanov V, Akhtar M, Tchekanov G, Dangas G, Shehzad MZ, Tio F, Adamian M, Colombo A, Roubin G, Leon MB, Moses JW, Kipshidze NN (2003) Transplantation of autologous endothelial cells induces angiogenesis. Pacing Clin Electrophysiol 26:496PubMedCrossRef
18.
go back to reference Huang YC, Khait L, Birla RK (2007) Contractile three-dimensional bioengineered heart muscle for myocardial regeneration. J Biomed Mater Res A 80:719PubMedCrossRef Huang YC, Khait L, Birla RK (2007) Contractile three-dimensional bioengineered heart muscle for myocardial regeneration. J Biomed Mater Res A 80:719PubMedCrossRef
19.
go back to reference Jockenhoevel S, Zund G, Hoerstrup SP, Chalabi K, Sachweh JS, Demircan L, Messmer BJ, Turina M (2001) Fibrin gel—advantages of a new scaffold in cardiovascular tissue engineering. Eur J Cardiothorac Surg 19:424PubMedCrossRef Jockenhoevel S, Zund G, Hoerstrup SP, Chalabi K, Sachweh JS, Demircan L, Messmer BJ, Turina M (2001) Fibrin gel—advantages of a new scaffold in cardiovascular tissue engineering. Eur J Cardiothorac Surg 19:424PubMedCrossRef
20.
go back to reference Stevens K, Kreutziger K, Dupras S, Korte F, Regnier M, Muskheli V, Nourse M, Bendixen K, Reinecke H, Murry C (2009) Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci USA 106:16568PubMedCrossRef Stevens K, Kreutziger K, Dupras S, Korte F, Regnier M, Muskheli V, Nourse M, Bendixen K, Reinecke H, Murry C (2009) Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci USA 106:16568PubMedCrossRef
21.
go back to reference Tulloch NL, Muskheli V, Razumova MV, Korte FS, Regnier M, Hauch KD, Pabon L, Reinecke H, Murry CE (2011) Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 109:47PubMedCentralPubMedCrossRef Tulloch NL, Muskheli V, Razumova MV, Korte FS, Regnier M, Hauch KD, Pabon L, Reinecke H, Murry CE (2011) Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 109:47PubMedCentralPubMedCrossRef
22.
go back to reference Koutsioumpa M, Hatziapostolou M, Mikelis C, Koolwijk P, Papadimitriou E (2009) Aprotinin stimulates angiogenesis and human endothelial cell migration through the growth factor pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta. Eur J Pharmacol 602:245PubMedCrossRef Koutsioumpa M, Hatziapostolou M, Mikelis C, Koolwijk P, Papadimitriou E (2009) Aprotinin stimulates angiogenesis and human endothelial cell migration through the growth factor pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta. Eur J Pharmacol 602:245PubMedCrossRef
23.
go back to reference Cholewinski E, Dietrich M, Flanagan TC, Schmitz-Rode T, Jockenhoevel S (2009) Tranexamic acid–an alternative to aprotinin in fibrin-based cardiovascular tissue engineering. Tissue Eng Part A 15:3645PubMedCrossRef Cholewinski E, Dietrich M, Flanagan TC, Schmitz-Rode T, Jockenhoevel S (2009) Tranexamic acid–an alternative to aprotinin in fibrin-based cardiovascular tissue engineering. Tissue Eng Part A 15:3645PubMedCrossRef
24.
go back to reference Ahmed TA, Griffith M, Hincke M (2007) Characterization and inhibition of fibrin hydrogel-degrading enzymes during development of tissue engineering scaffolds. Tissue Eng 13:1469PubMedCrossRef Ahmed TA, Griffith M, Hincke M (2007) Characterization and inhibition of fibrin hydrogel-degrading enzymes during development of tissue engineering scaffolds. Tissue Eng 13:1469PubMedCrossRef
25.
go back to reference McEvoy MD, Reeves ST, Reves JG, Spinale FG (2007) Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg 105:949PubMedCrossRef McEvoy MD, Reeves ST, Reves JG, Spinale FG (2007) Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg 105:949PubMedCrossRef
26.
go back to reference Bull DA, Maurer J (2003) Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg 75:S735PubMedCrossRef Bull DA, Maurer J (2003) Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg 75:S735PubMedCrossRef
27.
go back to reference Hickerson WL, Nur I, Meidler R (2011) A comparison of the mechanical, kinetic, and biochemical properties of fibrin clots formed with two different fibrin sealants. Blood Coagul Fibrinolysis 22:19PubMedCrossRef Hickerson WL, Nur I, Meidler R (2011) A comparison of the mechanical, kinetic, and biochemical properties of fibrin clots formed with two different fibrin sealants. Blood Coagul Fibrinolysis 22:19PubMedCrossRef
28.
go back to reference Buser Z, Kuelling F, Liu J, Liebenberg E, Thorne KJ, Coughlin D, Lotz JC (1976) Biological and biomechanical effects of fibrin injection into porcine intervertebral discs. Spine 36:E1201CrossRef Buser Z, Kuelling F, Liu J, Liebenberg E, Thorne KJ, Coughlin D, Lotz JC (1976) Biological and biomechanical effects of fibrin injection into porcine intervertebral discs. Spine 36:E1201CrossRef
29.
go back to reference Lorentz KM, Kontos S, Frey P, Hubbell JA (2011) Engineered aprotinin for improved stability of fibrin biomaterials. Biomaterials 32:430PubMedCrossRef Lorentz KM, Kontos S, Frey P, Hubbell JA (2011) Engineered aprotinin for improved stability of fibrin biomaterials. Biomaterials 32:430PubMedCrossRef
30.
go back to reference Ye Q, Zünd G, Benedikt P, Jockenhoevel S, Hoerstrup SP, Sakyama S, Hubbell JA, Turina M (2000) Fibrin gel as a three dimensional matrix in cardiovascular tissue engineering. Eur J Cardiothorac Surg 17:587PubMedCrossRef Ye Q, Zünd G, Benedikt P, Jockenhoevel S, Hoerstrup SP, Sakyama S, Hubbell JA, Turina M (2000) Fibrin gel as a three dimensional matrix in cardiovascular tissue engineering. Eur J Cardiothorac Surg 17:587PubMedCrossRef
31.
go back to reference Smith JD, Chen A, Ernst LA, Waggoner AS, Campbell PG (2007) Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels. Bioconjug Chem 18:695PubMedCrossRef Smith JD, Chen A, Ernst LA, Waggoner AS, Campbell PG (2007) Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels. Bioconjug Chem 18:695PubMedCrossRef
32.
go back to reference Fritz H, Wunderer G (1983) Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 33:479PubMed Fritz H, Wunderer G (1983) Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 33:479PubMed
33.
go back to reference Carmona P, Molina M, Rodríguez-Casado A (2003) Raman study of the thermal behaviour and conformational stability of basic pancreatic trypsin inhibitor. Eur Biophys J 32:137PubMedCrossRef Carmona P, Molina M, Rodríguez-Casado A (2003) Raman study of the thermal behaviour and conformational stability of basic pancreatic trypsin inhibitor. Eur Biophys J 32:137PubMedCrossRef
34.
go back to reference Bryers JD, Giachelli CM, Ratner BD (2012) Engineering biomaterials to integrate and heal: the biocompatibility paradigm shifts. Biotechnol Bioeng 109:1898PubMedCentralPubMedCrossRef Bryers JD, Giachelli CM, Ratner BD (2012) Engineering biomaterials to integrate and heal: the biocompatibility paradigm shifts. Biotechnol Bioeng 109:1898PubMedCentralPubMedCrossRef
35.
go back to reference Thompson WD, Smith EB, Stirk CM, Marshall FI, Stout AJ, Kocchar A (1992) Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J Pathol 168:47PubMedCrossRef Thompson WD, Smith EB, Stirk CM, Marshall FI, Stout AJ, Kocchar A (1992) Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J Pathol 168:47PubMedCrossRef
36.
go back to reference Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM (1987) Fibrin containing gels induce angiogenesis: implications for tumor stroma generation and wound healing. Lab Invest 57:673PubMed Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM (1987) Fibrin containing gels induce angiogenesis: implications for tumor stroma generation and wound healing. Lab Invest 57:673PubMed
37.
go back to reference van Hinsbergh VW, Collen A, Koolwijk P (2001) Role of fibrin matrix in angiogenesis. Ann NY Acad Sci 936:426PubMedCrossRef van Hinsbergh VW, Collen A, Koolwijk P (2001) Role of fibrin matrix in angiogenesis. Ann NY Acad Sci 936:426PubMedCrossRef
38.
go back to reference Jurasz P, Santos-Martinez MJ, Radomska A, Radomski MW (2006) Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis. J Thromb Haemost 4:1095PubMedCrossRef Jurasz P, Santos-Martinez MJ, Radomska A, Radomski MW (2006) Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis. J Thromb Haemost 4:1095PubMedCrossRef
39.
go back to reference Radziwon-Balicka A, de la Moncada Rosa C, Zielnik B, Doroszko A, Jurasz P (2013) Temporal and pharmacological characterization of angiostatin release and generation by human platelets: implications for endothelial cell migration. PLoS One 8:e59281PubMedCentralPubMedCrossRef Radziwon-Balicka A, de la Moncada Rosa C, Zielnik B, Doroszko A, Jurasz P (2013) Temporal and pharmacological characterization of angiostatin release and generation by human platelets: implications for endothelial cell migration. PLoS One 8:e59281PubMedCentralPubMedCrossRef
40.
go back to reference Madden LR, Mortisen DJ, Sussman EM, Dupras SK, Fugate JA, Cuy JL, Hauch KD, Laflamme MA, Murry CE, Ratner BD (2010) Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc Natl Acad Sci USA 107:15211PubMedCrossRef Madden LR, Mortisen DJ, Sussman EM, Dupras SK, Fugate JA, Cuy JL, Hauch KD, Laflamme MA, Murry CE, Ratner BD (2010) Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc Natl Acad Sci USA 107:15211PubMedCrossRef
41.
go back to reference Hill GE, Diego RP, Stammers AH, Huffman SM, Pohorecki R (1998) Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. Ann Thorac Surg 65:66PubMedCrossRef Hill GE, Diego RP, Stammers AH, Huffman SM, Pohorecki R (1998) Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. Ann Thorac Surg 65:66PubMedCrossRef
42.
go back to reference McEvoy MD, Taylor AG, Zavadzkas JA, Mains IM, Ford RL, Stroud RE, Jeffords LB, Beck CU, Reeves ST, Spinale FG (2008) Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion. Ann Thorac Surg 86:568PubMedCentralPubMedCrossRef McEvoy MD, Taylor AG, Zavadzkas JA, Mains IM, Ford RL, Stroud RE, Jeffords LB, Beck CU, Reeves ST, Spinale FG (2008) Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion. Ann Thorac Surg 86:568PubMedCentralPubMedCrossRef
43.
go back to reference Asimakopoulos G, Lidington EA, Mason J, Haskard DO, Taylor KM, Landis RC (2001) Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg 122:123PubMedCrossRef Asimakopoulos G, Lidington EA, Mason J, Haskard DO, Taylor KM, Landis RC (2001) Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg 122:123PubMedCrossRef
44.
go back to reference Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA (1996) Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 83:696PubMed Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA (1996) Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 83:696PubMed
45.
go back to reference Brown BN, Valentin JE, Stewart-Akers AM, McCabe GP, Badylak SF (2009) Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials 30:1482PubMedCentralPubMedCrossRef Brown BN, Valentin JE, Stewart-Akers AM, McCabe GP, Badylak SF (2009) Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials 30:1482PubMedCentralPubMedCrossRef
46.
go back to reference Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA (2001) Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 194:809PubMedCentralPubMedCrossRef Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA (2001) Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 194:809PubMedCentralPubMedCrossRef
48.
go back to reference Obokata H, Yamato M, Tsuneda S, Okano T (2011) Reproducible subcutaneous transplantation of cell sheets into recipient mice. Nat Protoc 6:1053PubMedCrossRef Obokata H, Yamato M, Tsuneda S, Okano T (2011) Reproducible subcutaneous transplantation of cell sheets into recipient mice. Nat Protoc 6:1053PubMedCrossRef
49.
go back to reference Lindbom L, Arfors KE (1984) Non-homogeneous blood flow distribution in the rabbit tenuissimus muscle: differential control of total blood flow and capillary perfusion. Acta Physiol Scand 122:225PubMedCrossRef Lindbom L, Arfors KE (1984) Non-homogeneous blood flow distribution in the rabbit tenuissimus muscle: differential control of total blood flow and capillary perfusion. Acta Physiol Scand 122:225PubMedCrossRef
Metadata
Title
Proangiogenic microtemplated fibrin scaffolds containing aprotinin promote improved wound healing responses
Authors
Kassandra S. Thomson
Sarah K. Dupras
Charles E. Murry
Marta Scatena
Michael Regnier
Publication date
01-01-2014
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 1/2014
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-013-9388-z

Other articles of this Issue 1/2014

Angiogenesis 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.